The outcome of patients with aneurysmal subarachnoid hemorrhage (SAH) has improved slowly over the past 25 years. This improvement may be due to early aneurysm repair by endovascular or open means, use of nimodipine, and better critical care management. Despite this improvement, mortality remains at about 40%, and many survivors have permanent neurologic, cognitive, and neuropsychologic deficits. Randomized clinical trials have tested pharmacologic therapies, but few have been successful. There are numerous explanations for the failure of these trials, including ineffective interventions, inadequate sample size, treatment side effects, and insensitive or inappropriate outcome measures. Outcome often is evaluated on a good-bad dichotomous scale that was developed for traumatic brain injury 40 years ago. To address these issues, we established the Subarachnoid Hemorrhage International Trialists (SAHIT) data repository. The primary aim of the SAHIT data repository is to provide a unique resource for prognostic analysis and for studies aimed at optimizing the design and analysis of phase III trials in aneurysmal SAH. With this aim in mind, we convened a multinational investigator meeting to explore merging individual patient data from multiple clinical trials and observational databases of patients with SAH and to create an agreement under which such a group of investigators could submit data and collaborate. We welcome collaboration with other investigators.
Bibliographical noteFunding Information:
Conflict of interest statement: This work was funded by a grant from the Canadian Institutes for Health Research . Michael D. Cusimano receives grant support from the Canadian Institutes for Health Research . Nima Etminan receives grant support from Physicians Services Incorporated Foundation . David Hasan receives grant funding from National Institutes of Health and Brain Aneurysm Foundation . Peter Le Roux receives research funding from the National Institutes of Health and Integra and is a consultant for Codman, Integra and Edge Therapeutics. R. Loch Macdonald receives grant funding from the Canadian Institutes for Health Research , Heart and Stroke Foundation of Canada , Canadian Stroke Network , Brain Aneurysm Foundation , and Physicians Services Incorporated Foundation and is a consultant for Actelion Pharmaceuticals, Ltd., and Chief Scientific Officer of Edge Therapeutics, Inc. Stephan Mayer is a consultant for Actelion Pharmaceuticals, Ltd. Andrew Molyneux is a consultant for Micrus Endovascular and receives grant support from the Medical Research Council UK and Cerecyte Coil Trial . Tom A. Schweizer receives grant support from the Heart and Stroke Foundation of Canada , the Canadian Institutes of Health Research , and the Ontario Ministry of Research and Innovation . Michael Todd receives grant support from the National Institutes of Health . James Torner receives grant support from the National Institutes of Health . Mervyn D. I. Vergouwen receives grant support from the Netherlands Thrombosis Foundation and Netherlands Heart Foundation . George K. C. Wong receives grant support from the Hong Kong Food and Health Bureau and the Hong Kong University Grant Committee .
- Cerebral aneurysm
- Clinical trial
- Subarachnoid hemorrhage